Influencing the fibrinolytic activity by antithrombotics in patients with atherosclerosis
Norden, C.; Reimann, H.; Grunow, G.; Misselwitz, F.; Taube, C.; Heine, H.
Folia Haematologica 116(6): 907-913
1989
ISSN/ISBN: 0323-4347 PMID: 2483710 Document Number: 336230
In 106 atherosclerotic patients receiving an anticoagulant therapy and 91 patients receiving acetylsalicylic acid, fibrinogen and fibrin degradation products were determined as well as euglobulin lysis before and after venous occlusion. Platelet function data and thromboxane (TXB2) were also determined. Since "moderate" anticoagulant therapy with thromboplastin time values 26-40% results in deteriorated fibrinolysis data, anticoagulant therapy is strictly to remain within the therapeutic range of 15-20% up to 25% thromboplastin time at maximum. Treatment with acetylsalicylic acid proved useful on condition that the required dose was determined individually. This type of treatment will then be able to reduce the thromboxane level and positively influence the fibrinolytic potential.